Testing version — LOERadar is in active testing. Features and data may change.
ELOXATIN (OXALIPLATIN) | LOERadar
ELOXATIN
NDA
OXALIPLATIN | N021759 | SANOFI AVENTIS US LLC
3 strengths0 unique patents0 unique exclusivities
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (3)
Sort:
#001 — 50MG/10ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▴
INJECTABLE;INTRAVENOUS | Approved: Jan 31, 2005
No patent or exclusivity listings for this strength.
#002 — 100MG/20ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
INJECTABLE;INTRAVENOUS | Approved: Jan 31, 2005
#003 — 200MG/40ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**